| |
Diagnosis
|
n
|
Sex (male/female)
|
Age (years)
|
MMSE score
|
Aβ1–42 (pg/ml)
|
Total tau (pg/ml)
|
Phosphorylated tau (pg/ml)
|
oAβ (pg/ml)
|
|---|
|
Cohort 1
|
AD
|
10
|
3/7
|
72
|
N/A
|
442.6 ± 27.4
|
1101 ± 112.5
|
119.1 ± 8.2
|
0.9 ± 0.2
|
|
(54 to 84)
| |
(316, 568)
|
(609, 1,850)
|
(81,172)
|
(0.4, 2.4)
|
|
Normal
|
10
|
5/5
|
72
|
N/A
|
829.8 ± 57.3
|
239.5 ± 15.8
|
35.9 ± 2.1
|
0.7 ± 0.1
|
|
(62 to 81)
| |
(607, 1,100)
|
(129, 315)
|
(26, 45)
|
(0.4, 1.4)
|
|
Cohort 2
|
AD
|
10
|
6/4
|
72
|
18
|
184.4 ± 11.2
|
154.9 ± 22.5
|
34.4 ± 3.2
|
0.2 ± 0.0
|
|
(50 to 86)
|
(11 to 20)
|
(147, 236)
|
(70, 247)
|
(22, 47)
|
(0.1, 0.3)
|
|
MCI
|
10
|
6/4
|
81
|
25
|
250.0 ± 25.6
|
142.3 ± 15.6
|
31.3 ± 4.3
|
0.3 ± 0.1
|
|
(76 to 89)
|
(23 to 28)
|
(165, 383)
|
(80, 207)
|
(17, 59)
|
(0.1, 0.8)
|
|
Normal
|
10
|
4/6
|
79
|
28
|
251.1 ± 34.1
|
58.8 ± 6.4
|
16.7 ± 1.8
|
0.2 ± 0.0
|
|
(75 to 82)
|
(27 to 29)
|
(126, 399)
|
(36, 84)
|
(10, 25)
|
(0, 0.4)
|
|
Cohort 3
|
MCI
|
23
|
16/7
|
75
|
28
|
386.6 ± 30.0
|
152.4 ± 29.4
|
46.1 ± 5.1
|
0.9 ± 0.1
|
|
(60 to 85)
|
(25 to 30)
|
(201, 599)
|
(39, 530)
|
(20, 90)
|
(0.3, 2.7)
|
|
Normal
|
17
|
7/10
|
70
|
29
|
475.4 ± 23.1
|
95.5 ± 20.0
|
30.7 ± 5.3
|
0.6 ± 0.1
|
|
(55 to 86)
|
(27 to 30)
|
(352, 590)
|
(26, 285)
|
(11, 77)
|
(0.3, 1.3)
|
- Data presented as mean ± standard error of the mean (range). AD, Alzheimer’s disease; MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; oAβ, amyloid-beta oligomers.
